STOCKHOLM, May 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January - March 2025 on Wednesday, May 21, 2025, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on May 21, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the first quarter report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.
Webcast: https://bioarctic.events.inderes.com/q1-report-2025/register

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/bioarctic/q1-report-2025/dial-in

The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.

---

For more information, please contact:
Anders Martin-Löf, CFO
Phone: +46 70 683 79 77
E-mail: anders.martin-lof@bioarctic.com

This information was submitted for publication at 08:30 a.m. CET on May 13, 2025.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/invitation-to-presentation-of-bioarctic-s-first-quarter-report-for-january---march-2025-on-may-21-at,c4148987

The following files are available for download:


     
     https://mb.cision.com/Main/9978/4148987/3442685.pdf Invitation to presentation of BioArcticâEUR(TM)s first quarter report
                                                             for January -March 2025

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-bioarctics-first-quarter-report-for-january---march-2025-on-may-21-at-9-30-am-cet-302453517.html

Tags

More Like This

Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET

Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET

Implantica presents the first quarter 2025 on May 9 at 15:00 CEST

LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024

Implantica presents the first quarter 2024 on May 15 at 15:00 CEST

Invitation to the presentation of Calliditas´s interim report January - March 2024